Equities

MediNavi AG

MDQ:HAM

MediNavi AG

Actions
  • Price (EUR)5.25
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-25.00%
  • Beta0.3315
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medinavi AG is a Germany-based company holding company of its wholly-owned MediKompass GmbH, which is the Company's operating subsidiary. MediKompass GmbH operates an Online reverse auction platform in the field of medicine and healthcare. It operates four websites: www.medikompass.de, www.zahngebot.de, www.schoenheitsgebot.de and www.tierartzkosten.de. Those websites enable exchange of services, where doctors have access to patients and patients can choose offers for their conditions, as well as obtain a second medical opinion. Through its websites, the Company operates on the general health market, dental market and cosmetic surgery market. On March 5, 2012, the Company announced establishment of new subsidiary, DocMatch GmbH.

  • Revenue in EUR (TTM)--
  • Net income in EUR--
  • Incorporated2009
  • Employees--
  • Location
    MediNavi AGHausener Weg 29MUENCHEN 60489GermanyDEU
  • Phone+49 8 914330170
  • Fax+49 89 124138811
  • Websitehttps://medinavi.de
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Pharnext SCA150.00k-31.55m97.51k44.00------0.65-26,278,830.00-26,278,830.00171.43-17,532.990.0186--0.0298---391.03-128.26---367.63-22.54---21,035.67-4,413.23---------99.34---25.57---29.58--
Paion AG-100.00bn-100.00bn211.06k64.00---------------0.4074-----------24.86---34.32-------52.400.5078--1.17--366.4241.7497.34--129.37--
Bio Vitos Pharma AB256.18k-1.10m352.58k1.00--1.078.001.38-0.2547-0.25470.05330.11190.09890.005.382,983,990.00-42.63-31.11-44.50-32.92100.00---431.21-1,026.764.27--0.00--126.97--13.64------
European Institute of Science AB58.89k-236.78k442.05k0.00--1.97--7.51-4.23-4.231.051.930.24351.249.46---97.91-93.04-105.11-103.1459.3367.01-402.04-518.825.70--0.00--13.698.540.4062------
MediNavi AG-100.00bn-100.00bn452.84k--------------------------------------------------------------
QuiaPEG Pharmaceuticals Holding AB0.00-1.42m457.94k8.00--0.3498-----3.51-3.510.000.20470.00-------50.53-95.67-100.54-207.86--262.59---5,002.50---15.340.00------17.75--47.06--
2cureX AB13.31k-2.65m531.96k----0.4526--39.98-1.75-1.750.00880.77770.0048--0.0838---95.89-38.21-108.66-43.48-6,889.68-22,153.06-19,883.23-38,685.30---46.08----72.22---3.52------
Lipidor AB6.61k-986.09k537.34k--------81.29-0.3964-0.39640.0027-0.32230.0084--5.31---124.54-59.41---75.10-----14,916.88-643.36--------73.33-20.3372.24------
XP Chemistries AB56.98k-690.15k561.43k2.00--0.2546--9.85-0.2846-0.28460.02130.2750.0230.20845.99331,845.00-27.79---29.36--50.57---1,211.24--5.79--0.00---37.14---1.55------
Data as of May 17 2024. Currency figures normalised to MediNavi AG's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.